The effects of tirzepatIDE on coronAry pLaque lipid content and myocardial microvascular function in overweight and obese people with CORonary disease

Steno Diabetes Center Copenhagen0 个研究点目标入组 124 人开始时间: 2024年4月5日最近更新: 2024年7月22日

试验速览

暂无简介。

•BMI equal to or above 27 kg/m2, Age 18 years or older, Referred to coronary angiography (CAG) due to stable angina, Coronary atheromatosis by angiography (obstructive or non-obstructive), Lipid core burden index (LCBI) (4mm) >200 by near-infrared spectroscopy (NIRS) in a vessel not subjected to coronary intervention

•History of diabetes or HbA1c =48 mmol/mol (6.5%) at baseline, Family or history of multiple endocrine neoplasia (MEN) type 2 or familial medullary thyroid carcinoma (FMTC), Left main stenosis (=50% diameter or haemodynamically significant), Chronic total occlusion of any major coronary vessel, Treatment with glucagon-like peptide 1 (GLP-1) agonists, History of coronary artery bypass surgery (CABG), Planned cardiovascular intervention (including percutaneous coronary intervention, cardiac surgery or transcatheter valve intervention) at time of randomisation, History of heart failure New York Heart Association (NYHA) class III or IV, Left ventricular ejection fraction (LVEF) =35%, Estimated glomerular filtration rate (eGFR <30 ml/min/1.53 m2), History of pancreatitis or plasma amylase >3 times upper normal limit, Pregnancy or planned pregnancy

发起方